GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Oncology Pharma ONPH · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.04

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Net income

−$5,820

FY2019FY2026

Free cash flow

—

FY2019FY2026

Shareholders' equity

—

FY2019FY2026

Income statement

Fiscal years

FY2026FY2022FY2021FY2020FY2019
Gross profit——−$779−$1,109−$1,109
Operating income−$5,820−$62,050−$14.4m−$403,880−$818,860
Net income−$5,820−$104.6m−$97.5m−$207,556−$850,396
Diluted earnings per share-0.00-2.71-1.19-0.00-0.01

Balance sheet

At each fiscal year end

FY2026FY2022FY2021FY2020FY2019
Total assets—$2.1m$347,554$230,855$190,541
Cash and short-term investments—$3,963$8,954$1,805$6,708
Total liabilities—$875,471$517,565$294,519$403,159
Debt—$662,084$238,385$129,410$238,050
Shareholders' equity—$1.2m−$170,012−$63,664−$212,618
Shares outstanding82m39m82m82m82m

Cash flow

Fiscal years

FY2026FY2022FY2021FY2020FY2019
Cash from operations—$368,609−$117,076−$22,414−$36,907
Capital spending——−$4——
Free cash flow—$368,609−$117,080−$22,414−$36,907

Latest quarters

By quarter end

Dec 2025Dec 2022Sept 2022Jun 2022Sept 2013Jun 2013Mar 2013Dec 2011
Revenue————$18,000$1,400$10,200$472,306
Gross profit————$18,000$900—$472,306
Operating income−$820−$6,380−$83,460−$10,280−$22.0m$22,700−$14,500−$354,085
Net income−$820−$254,880−$5.3m−$23,509−$22.0m$22,700−$186,000−$375,111
Diluted earnings per share-0.00-0.01-0.14-0.00-19,950,638.0021,648.57-225,798.03—
Total assets—$2.1m$2.1m$2.1m$450,300$212,100$198,600$403,025
Cash and short-term investments—$398$1,783$1,183$13,400$19,000$9,300—
Debt—$777,620$773,220$689,584$593,300$389,400$410,900—
Shareholders' equity—$1.1m$1.1m$1.2m−$172,700−$183,000−$220,300−$407,304

Growth per year

Compound annual rate

3 years5 years10 years
Operating income-92.6%-62.8%-43.1%
Net income-96.1%-63.1%-42.7%

Valuation history

At each fiscal year end

FY2026
Price to earnings-634.6

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return533233%51100%-99%-89%3810%-65%1758%-24%2226%966%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 9 Oct 2020
  • 10000-to-1 reverse split · 4 Jan 2016
  • 500-to-1 reverse split · 8 Jul 2013

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.